Lobular Breast Cancer in Man – Case Report and Review of the Literature

Česká verzia

Authors: J. Navrátil ¹; K. Petrakova ¹; R. Nenutil ²; R. Vyzula ¹; M. Svoboda ¹
Authors place of work: Klinika komplexní onkologické péče, Masarykův onkologický ústav, Brno2 Oddělení onkologické patologie, Masarykův onkologický ústav, Brno ¹
Published in the journal: Klin Onkol 2014; 27(2): 97-102
Category: Reviews

Summary

Case:
Herein we report a case of a man with a B‑ cell non‑Hodgkin lymfoma, primarily diagnosed by topographic and morfology tokens as lobular breast carcinoma and, as such, it was treated by chemotherapy and endocrine therapy. The treatment resulted in complete remission for 3,5 years. However, the subsequent relapses that arised in retrocrural and left axilary area did not respond adequately to breast cancer targeted chemotherapy. Therefore the patient underwent re‑exstirpation of axillary lymph node yielding a surprising histology finding of folicular lymphoma. The primary biopsy specimen was histologicaly re‑evaluated and the initial diagnosis was re‑classified as folicular lymphoma. The patient was given an adequate chemotherapy and targeted treatment that established a complete remission. Six months afterwards there was a relapse detected in the retrocrural area. The patient underwent palliative radiotherapy that brought about complete remission and, so far, he is in good condition. It has been eight years since the cancer diagnosis was established. This case report is appended by review of literature dealing with diagnostic confusion of these two malignancies.

Conclusion:
Re‑ biopsy plays a significant role in case of treatment strategy controversies, predominantly on condition of atypical course of malignant disease. It should always be considered in case of cancer relapse, especially if the phenotype specfication could affect the treatment decision.

Key words:
breast cancer lobular – folicular lymphoma – diagnosis – histology – male

Zdroje

1. Úzis.cz [internetová stránka]. Ústav zdravotnických informací a statistiky ČR. Národní onkologický registr. © ÚZIS ČR 2010– 2014 [citováno 10. 10. 2013]. Dostupné z: www.uzis.cz/ registry‑ nzis/ nor.

2. Talwalkar SS, Miranda RN, Valbuena JR et al. Lymphomas involving the breast: a study of 106 cases comparing localized and disseminated neoplasms. Am J Surg Pathol 2008; 32(9): 1299– 1309.

3. Sanna G, Lorizzo K, Rotmensz N et al. Breast cancer in Hodgkin‘s disease and non‑Hodgkin‘s lymphoma survivors. Ann Oncol 2007; 18(2): 288– 292.

4. Sheen‑ Chen SM, Eng HL. Development of malignant lymphoma subsequent to breast cancer. Eur J Cancer Care (Engl) 2007; 16(4): 331– 332.

5. Barranger E, Marpeau O, Uzan S et al. Axillary sentinel node involvement by breast cancer coexisting with B‑ cell follicular lymphoma in nonsentinel nodes. Breast J 2005; 11(3): 227– 228.

6. Cuff KE, Dettrick AJ, Chern B. Synchronous breast cancer and lymphoma: a case series and a review of the literature. J Clin Pathol 2010; 63(6): 555– 557.

7. Nagasaki E, Furuta N, Shinozaki E et al. Simultaneous detection of both non‑Hodgkin‘s lymphoma cells and breast cancer cells in pleural effusion: a case report. Gan To Kagaku Ryoho 2003; 30(10): 1523– 1527.

8. Papajík T, Trněný M, Vášová I et al. Epidemiologie ne‑ hodgkinových lymfomů v České republice, Evropě a Severní Americe. Onkologie 2009; 3(3): 141– 146.

9. Benešová K, Trněný M. Folikulární lymfom. Postgrad Med 2010; 6: 692– 696.

10. Češka R et al (eds). Lymfomy non‑Hodgkinovy. Interna. Praha: Triton 2010.

11. Taubman K, McKay M. Axillary lymphoma masque-rading as inflammatory breast cancer. Biomed Imaging Interv J 2006; 2(3): e36.

12. Pereira EM, Maeda SA, Reis‑ Filho JS. Sarcomatoid variant of anaplastic large cell lymphoma mimicking a primary breast cancer: a challenging diagnosis. Arch Pathol Lab Med 2002; 126(6): 723– 726.

13. Anne N, Pallapothu R. Lymphoma of the breast: a mimic of inflammatory breast cancer. World J Surg Oncol 2011; 9: 125.

14. Pruthi S, Stafyla VK, Phillips SW et al. Primary mammary (non‑Hodgkin) lymphoma presenting as locally advanced breast cancer. Mayo Clin Proc 2004; 79(10): 1310– 1314.

15. Sapino A, Cassoni P, Ferrero E et al. Estrogen receptor α is a novel marker expressed by follicular dendritic cells in lymph nodes and tumor‑associated lymphoid infiltrates. Am J Pathol 2003; 163(4): 1313– 1320.

16. Shim GJ, Gherman D, Kim HJ et al. Differential expression of oestrogen receptors in human secondary lymphoid tissues. J Pathol 2006; 208(3): 408– 414.

17. Zekri JM, Hough RE, Davies JM at al. Phase II study of docetaxel in patients with relapsed or refractory malignant lymphoma. Br J Cancer 2003; 88(9): 1335– 1338.

18. Budman DR, Petroni GR, Johnson JL et al. Phase II trial of docetaxel in non‑Hodgkin‘s lymphomas: a study of the Cancer and Leukemia Group B. J Clin Oncol 1997; 15(10): 3275– 3279.

19. Kahl BS, Bailey HH, Smith EP et al. Phase II study of weekly low‑dose paclitaxel for relapsed and refractory non‑Hodgkin‘s lymphoma: a Wisconsin Oncology Network Study. Cancer Invest 2005; 23(1): 13– 18.

20. Pro B, Hagemeister FB, McLaughlin P et al. Phase 2 study of fludarabine and paclitaxel in patients with recurrent low‑ grade non‑Hodgkin‘s lymphoma. Leuk Lymphoma 2006; 47(9): 1818– 1821.

21. Monfardini S, Aversa SM, Zoli V et al. Vinorelbine and prednisone in frail elderly patients with intermediate‑ high grade non‑Hodgkin‘s lymphomas. Ann Oncol 2005; 16(8): 1352– 1358.

22. Guglielmi C, Amadori S, Anselmo AP et al. Sequential combination chemotherapy of high‑grade non‑Hodgkin‘s lymphoma with 5- fluorouracil, methotrexate, cytosine‑ arabinoside, cyclophosphamide, doxorubicin, vincristine, and prednisone (F‑ MACHOP). Cancer Invest 1987; 5(3): 159– 169.

23. Ezzat AA, Ibrahim EM, Start RK et al: Adding high‑dose tamoxifen to CHOP does not influence response or survival in aggressive non‑Hodgkin‘s lymphoma: an interim analysis of a randomized phase III trial. Med Oncol 2000; 17(1): 39– 46.

24. El‑ Yazigi A, Berry J, Ezzat A et al. Effect of tamoxifen on the pharmacokinetics of doxorubicin in patients with non‑Hodgkin‘s lymphoma. Ther Drug Monit 1997; 19(6): 632– 636.